Alliance for Clinical Trials in Oncology’s Post

A recent study published in JCO, involving over 7,000 lung cancer patients, found that over 14% had potentially germline variants (PGVs), with 63% in DNA damage repair (DDR) genes such as BRCA1, BRCA2, ATM, and CHEK2. The results recommend that clinicians should consider germline genetic testing for all lung cancer patients, as the frequencies of PGVs in genes like BRCA1, BRCA2 and mismatch repair genes were significantly higher than in unaffected individuals. #lungcancer #BRCA1 #BRCA2 #germline

Important information!!

Enriching insight in patient responses to targeted therapies by ex vivo tumor testing. VitroScan's Lieke Ceton and Timothy Sijsenaar will present our newest data on patients sensitivity to targeted therapies at the European Association for Cancer Research (EACR) - Innovative Cancer Science Cogress '24. Accumulating evidence indicates that a direct correlation between a mutated cancer gene and a response to a given therapy is too simplistic. Ex vivo tumor testing preserves the overall complexity of the tissue and cellular pathways that elicit response to treatment thus providing near patient testing. In addition, it assesses the response to targeted therapies in the context of the patients sensitivity to other drug classes in parallel. We are looking forward to connect during the meeting potentially via a discussion at the posters find us Tuesday 11 June 2024 - EACR2024-#0808. #EACR24, #targetedtherapy, #predictivetesting, #cancerresearch

This #FridayRead highlights the value of Immunologic Constant of Rejection signature (ICR) as a potential biomarker for the effectiveness of anti-PD1/PDL1 in lung cancer 👉 https://bit.ly/462pBgP Groups at APHM (Assistance Publique - Hopitaux de Marseille) and Institut Paoli-Calmettes identified a gene signature with a nCounter panel and revealed a strong link between the ICR classification and treatment response. 🔍 These results emphasize the impact of molecular signatures like ICR in tailoring personalized treatment strategies for cancer therapies. #GeneSignature #LungCancer #PrecisionMedicine

Additional data supporting MammaPrint® utility in treatment selection will be presented in a #ASCO24 poster by other investigators titled “Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancer Closely Resembles Triple Negative Breast Cancer: Results from Gene Expression Data from the ISPY2 Trial” [Rios-Hoyo, A., et al.]. Attend the poster session presentation on June 2nd from 9:00am – 12:00pm CT. View the poster here: https://lnkd.in/gFYypyMQ #ASCO24 #oncology #breastcancer

In honor of #BreastCancerAwareness month, I wanted to do a post about how #pharmacogenomics can impact breast cancer treatment. People with hormone-receptor-positive breast cancer are frequently started on anti-hormonal treatments to control the cancer and prevent recurrence. The most frequently used is tamoxifen. Tamoxifen is metabolized (processed) in the body by a gene named CYP2D6, to a more active form named endoxifen. If patients have less active forms of this gene, tamoxifen might not work well because sufficient levels of endoxifen won’t be produced. In these patients, guidelines recommended an alternative class of treatment, called aromatase inhibitors, instead. Pharmacogenomics isn’t just a novelty— it’s actually legitimate, scientific, and crucial to providing optimal care. #cancer #BreastCancer #innovation

I think it's so important to share posts like this to continue bringing awareness to breast cancer and the important role pharmacogenomic testing can play in helping these patients receive appropriate treatment based on THEIR genetics. If you or someone you know is interested in learning more about PGx testing and how it can help in selecting medications that will work best based on an individual's genetics, please leave me a message at: www.drmaryreeber.com

Hereditary Diffuse Gastric Cancer (HDGC) is caused by variants in the CDH1 gene and associated with diffuse gastric cancer and lobular breast cancer. If your patient has a personal or family history of these cancers, consider testing for #CDH1. #GeneChat #PrecisionMedicine #StomachCancerAwarenessMonth

The recent FDA approval of G12C KRAS inhibitors marks a crucial milestone in cancer treatment. Despite this, the initial response is limited and many patients relapse. A comprehensive KRAS-dependent transcriptional signature could be the key to broader and more durable responses. This research by Jeff Klomp and others, highlights a robust KRAS gene signature enriched in response to pharmacologic inhibition. This signature, driven by ERK MAPK activity, is essential for understanding how KRAS mutations drive cancer. Can these insights lead to better clinical outcomes for KRAS-mutant cancer patients? See link to original article in the comments below 👇 #CancerResearch #KRASInhibitors #PrecisionMedicine #Oncology 👉 Follow xCures Read our LinkedIn Newsletter: https://lnkd.in/dnNJV2ti https://xcures.com/ 👀

In honor of #BreastCancerAwareness month, I wanted to do a post about how #pharmacogenomics can impact breast cancer treatment. People with hormone-receptor-positive breast cancer are frequently started on anti-hormonal treatments to control the cancer and prevent recurrence. The most frequently used is tamoxifen. Tamoxifen is metabolized (processed) in the body by a gene named CYP2D6, to a more active form named endoxifen. If patients have less active forms of this gene, tamoxifen might not work well because sufficient levels of endoxifen won’t be produced. In these patients, guidelines recommended an alternative class of treatment, called aromatase inhibitors, instead. Pharmacogenomics isn’t just a novelty— it’s actually legitimate, scientific, and crucial to providing optimal care. #cancer #BreastCancer #innovation